MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

FBRX — Forte Biosciences, Inc. Common Stock

Nasdaq

Forte Biosciences, Inc. Common Stock

CompareBack to Screener
$76.99
+0.02(+0.03%)
O
76.97
H
77.00
L
76.96
V
1.4M
⏱️ End-of-day dataAs of Aug 26, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About FBRX

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJun 16, 2020
Employees22
Stock ExchangeNasdaq
Ticker SymbolFBRX
Websitehttps://www.fortebiorx.com

Key Financial Statistics

Market Cap$1.57B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$10.30 - $77.20
52-Week Avg Volume526.2K
VWAP$76.98
Transactions4,972
Total Recorded Bars2,355 days